KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride
This article was originally published in The Rose Sheet
Since acquiring Nature's Bounty in 2010 and taking the publicly traded firm private, Carlyle could have been at the helm longer than executives at the private equity firm intended or expected, exceeding the five-year plan typical for similar investments.
You may also be interested in...
Evidence uncovered at the headquarters of Solgar Polska indicates the firm has since 2010 been instructing retailers to fix prices for its wide range of supplements, according to the national competition regulator. The company is now facing a full investigation and potentially a substantial fine.
Consumer health product industry veteran executive Paul Sturman takes the helm at Nature's Bounty Co. on the day that private equity firm Kohlberg Kravis Roberts & Co. LP closed its acquisition of a controlling interest in the nutritional and health and wellness product manufacturer from Carlyle Group LP. The Ronkonkoma, N.Y.-based firm on Sept. 28 said Sturman has more than 30 years of experience in the sector, including leading Pfizer Inc.'s consumer product group and is a past chairman of the Consumer Healthcare Products Association. (Also see "KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride" - HBW Insight, 24 Jul, 2017.) Sturman succeeds Steve Cahillane, the second CEO Carlyle appointed in 2014 after acquiring Nature's Bounty, then NBTY Inc., in 2010 and taking the firm private. (Also see "Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane" - Pink Sheet, 20 Aug, 2014.)
Swander Pace expands Captek’s operations less than two years after acquiring the firm and seven months after investing in a protein supplement manufacturer as one of numerous private equity firms active in the nutritional products space.